Who should consider semaglutide with glycine The glycine formulation may be particularly beneficial for specific patient populations
Most findings so far come from animal studies and preclinical research, but the potential implications are significant
Those with severe gastrointestinal conditionssuch as gastroparesis or severe GERDmay face worsening symptoms, since semaglutide slows gastric emptying
Initial concerns were raised after findings from the cardiovascular outcome trial (CVOT), Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 6 (SUSTAIN 6), revealed a greater risk of DR-related complications, defined as the need for laser therapy, intravitreal injections, development of vitreous hemorrhage, and blindness, in semaglutide users compared to placebo (3.0% vs 1.8%, HR=1.76, P =.02)
are taking or have taken medicines called monoamine oxidase inhibitors (MAOIs) in the past 14 days